Depemokimab is an inhibitor of IL-5 ... GSK is also working on expanding the label of Nucala for treating chronic obstructive pulmonary disease (COPD) currently in phase III evaluation.

Depemokimab is designed to target IL-5 ... In September, the FDA expanded Dupixent’s label in the CRSwNP indication for use in adolescent patients aged 12 to 17 years. The drug has already ...

Depemokimab is currently not approved for use in any country. The phase III asthma programme consists of SWIFT-1 and SWIFT-2 in asthma with type 2 inflammation, with an open label extension study ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately controlled ...